Section Arrow
RPRX.NASDAQ
- Royalty Pharma plc
Quotes are at least 15-min delayed:2025/11/22 21:30 EST
Regular Hours
Last
 38.92
+0.53 (+1.38%)
Day High 
39.13 
Prev. Close
38.39 
1-M High
41.24 
Volume 
3.16M 
Bid
38.3
Ask
42.82
Day Low
38.31 
Open
38.57 
1-M Low
35.915 
Market Cap 
16.40B 
Currency 美元 
P/E 21.94 
%Yield 2.26 
10-SMA 39.02 
20-SMA 38.43 
50-SMA 36.99 
52-W High 41.24 
52-W Low 24.05 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
1.75/3.38
Enterprise Value
23.02B
Balance Sheet
Book Value Per Share
15.01
Cash Flow
Cash Flow Yield
0.11
Income Statement
Total Revenue
2.26B
Operating Revenue Per Share
5.44
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
OSRHOSR Holdings Inc.0.5626+0.1066+23.38%-- 
SGMOSangamo Therapeutics0.4234+0.0384+9.97%-- 
RXRXRecursion Pharmaceuticals4.17+0.32+8.31%-- 
CYPHCypherpunk Technologies Inc.2.28-0.66-22.45%-- 
ASBPAspire Biopharma Holdings Inc.0.0974-0.0003-0.31%-- 
Industry overview quotes are at least 15 minutes delayed
Business Description
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.